Peptides vs. Anabolics During a Cut: Fat Loss and Muscle

Two Paths to a Leaner Physique

You're deep in a cut. Hunger never really goes away and your strength is slipping. You're starting to look flat, and the worry every dieting lifter knows sets in: am I losing muscle?

For decades, the usual answer among bodybuilders was testosterone or an oral like Anavar (oxandrolone). Traditional anabolic-androgenic steroids (AAS) are effective at preserving lean mass in a calorie deficit; that part isn't in dispute. But they accomplish this by pushing androgen levels far above normal, often with significant consequences like shutting down your natural testosterone production.

Today, there's another set of tools: metabolic peptides, mainly the prescription GLP-1 drugs semaglutide and tirzepatide, along with growth hormone secretagogues sold as research chemicals. They aren't "safer steroids," because they don't do the same job. Steroids protect muscle directly; the GLP-1 drugs mostly change how much you eat.

Mechanism: The Sledgehammer vs. The Scalpel

To understand why you'd pick one over the other, you have to understand how they work. The mechanisms couldn't be more different, and that explains most of the gap in side effects.

The Anabolic Sledgehammer

Traditional anabolics, from testosterone to trenbolone, work primarily by binding to the androgen receptor (AR). This action directly increases nitrogen retention and muscle protein synthesis. When you're in a calorie deficit, your body is in a catabolic state, looking to break down muscle tissue for energy. Anabolics put a strong brake on this process, which is why lifters on a cycle tend to hold muscle through a deficit that would otherwise cost them some.

But the androgen receptor is found all over the body, not only in muscle. That's why the effects are so widespread. A 2014 Endocrine Society statement describes suppression of the hypothalamic-pituitary-testicular axis (HPTA), sometimes lasting months after a cycle, along with lower HDL and higher LDL cholesterol. Hair loss is a common androgenic effect, and 17α-alkylated orals such as oxandrolone are toxic to the liver (2015 review). It's an effective tool, but it's anything but precise.

The Peptide Scalpel

Peptides used for fat loss don't act on the androgen receptor. They work on entirely different pathways.

1. Growth Hormone Secretagogues (GHS): This category includes research peptides like CJC-1295 and ipamorelin, which prompt the pituitary gland to release more of your own growth hormone (GH). A 2009 Endocrine Reviews summary of human studies calls a marked increase in lipolysis (fat cells releasing stored fat as free fatty acids) the most prominent metabolic effect of GH. GH also works against insulin, which is why blood sugar can rise. But nobody has shown the secretagogues cause meaningful fat loss: the 2006 CJC-1295 studies in healthy adults measured hormone levels, not body fat. As of October 2026, neither peptide is approved anywhere. Our CJC-1295 fat-loss guide and ipamorelin fat-loss guide go further.

2. GLP-1 and GIP/GLP-1 Agonists: This newer class has far stronger evidence. Semaglutide and tirzepatide mimic your body's natural incretin hormones. Their effect on fat loss isn't primarily about boosting metabolic rate or directly breaking down fat. Instead, they work by:

   • Suppressing appetite via action in the hypothalamus.
   • Slowing gastric emptying, making you feel fuller for longer after a meal.
   • Improving glucose control and insulin sensitivity.

These are FDA-approved prescription medicines. In STEP 1, adults with obesity on semaglutide 2.4 mg weekly lost 14.9% of body weight on average over 68 weeks. In the SURMOUNT-5 head-to-head trial, tirzepatide produced 20.2% average weight loss versus 13.7% on semaglutide at 72 weeks, according to Lilly. As of October 2026, semaglutide also comes as the Wegovy pill (up to 25 mg daily on the label, approved December 2025) and Wegovy HD (7.2 mg weekly, approved March 2026). Research-use vials sold online aren't equivalent: they aren't approved products, and no regulator checks what's in them.

This is a different angle of attack. Anabolics might preserve muscle while you push through a diet, but a GLP-1 agonist makes the diet itself easier to stick to. The catch for a lifter is that part of the weight lost on these drugs is lean mass.

Holding Muscle on a GLP-1: The 2026 Trials

Lean-mass loss became a trial endpoint in 2026. In BELIEVE, a Phase 2 trial in 507 adults with obesity (Nature Medicine, March 2026), semaglutide 2.4 mg alone cut lean mass by about 5-7% over 48 weeks. Adding bimagrumab, an activin-receptor antibody given in the trial by IV infusion every 12 weeks, held that loss to about 1-2%. Fat made up 92% of the weight lost in the high-dose combination group, versus 71% on semaglutide 2.4 mg alone. Muscle spasms were bimagrumab's most common side effect.

Regeneron's COURAGE trial, presented at the EASD meeting on October 1, 2026, tested the myostatin antibody trevogrumab with semaglutide in 975 adults with obesity. Adding trevogrumab roughly halved the 6.6% lean-mass loss seen with semaglutide plus placebo at 26 weeks. A triple combination with the activin A antibody garetosmab had far more serious adverse events, and both deaths in the study occurred in that arm (no causal link was identified).

Neither antibody is approved, and the COURAGE authors say it hasn't been shown that preserved lean mass improves strength or function. The first approved myostatin-targeted drug, apitegromab (Isembyld), was cleared by FDA on September 11, 2026 for spinal muscular atrophy. It isn't approved for obesity or muscle building, and FDA notes an increased fracture risk. WADA's 2026 Prohibited List names both bimagrumab and apitegromab under S4.3, which bans this whole class at all times.

The Cost of Getting Lean: A Side-by-Side Look

Nothing is free. Every compound has a cost, and choosing your tool means choosing which side effects you're willing to manage. Anabolics have a well-documented list of baggage. Peptides have their own, and they're very different.

Looking at this table, the choice becomes clearer. If you can't tolerate HPTA shutdown, traditional anabolics are off the table. If you have a sensitive stomach, starting a GLP-1 at a high dose would likely be miserable; the Wegovy label starts at 0.25 mg weekly and raises the dose every 4 weeks for that reason. You're mostly trading hormonal risk for GI risk, with some muscle at stake.

Stacking: Using the Whole Toolbox

Many physique athletes combine these compounds. None of the combinations below has been tested in a controlled trial; they're described here as users report them.

• The Classic Pro Stack (AAS + GHS): For decades, bodybuilders have combined a testosterone base with a GH-releasing peptide or synthetic HGH. The anabolic provides the anti-catabolic shield, and users credit the GH side with fat loss and better sleep, though the secretagogue version has never been measured for fat loss.

• The Modern Appetite-Control Stack (AAS + GLP-1): This is a newer combination. Users describe a modest dose of testosterone or Primobolan to hold muscle while semaglutide suppresses hunger. No study has looked at the pairing. The risk users mention most is under-eating without noticing, including too little protein.

• The Non-Steroidal Stack (GHS + GLP-1): Lifters who want to avoid AAS often pair CJC-1295/ipamorelin with semaglutide or tirzepatide. Only the GLP-1 half has trial evidence, and it doesn't address lean-mass loss. The 2026 antibody trials test a prescription-track version of the idea instead: a GLP-1 drug plus a myostatin or activin blocker.

Choosing a Tool for a Cut

Which is better depends on your goal and the risks you'll accept.

Traditional anabolics are the most direct tool for muscle preservation. If your priority is to hold as much lean tissue as possible during a hard cut, and you're willing to accept HPTA shutdown and manage the other associated risks, anabolics do that specific job most directly.

GLP-1 drugs have the best evidence for the deficit itself. They make dieting easier through appetite and satiety signals, with side effects that are mostly digestive rather than hormonal. They don't protect muscle, though. GH secretagogues sit further back, with a plausible mechanism and no outcome data.

For tested athletes the rules differ by class. As of October 2026, WADA's Prohibited List doesn't include semaglutide or tirzepatide but bans AAS (S1) and GH secretagogues (S2.2.4). Our guide to peptides and sports rules covers the details, and our broader comparison of peptides and anabolic steroids looks beyond cutting.

What We Still Don't Know

• Whether lean mass preserved by bimagrumab or trevogrumab means more strength or function, especially in trained lifters rather than adults with obesity.
• How GLP-1 drugs interact with anabolic steroids; no study has tested the pairing.
• Whether GH secretagogues change body composition in lean adults who train.